Drugs in Dev.
Immunology
Phase III
Israel 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : U.S. patents for opaganib combination for the treatment of Ebola virus disease provides patent protection until 2035. Opaganib also undergoing two oncology Phase 2 U.S. studies as well as several development programs for inflammatory and viral indication...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
August 23, 2021
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : TEV-45779
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : TEV-45779 is a drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Chronic Urticaria.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : TEV-45779
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Teva Pharmaceutical Industries
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Public Offering
RedHill Biopharma Announces $10 Million Bought Deal Offering of American Depositary Shares
Details : The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
March 01, 2021
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Public Offering
RedHill Biopharma Announces $10 Million Bought Deal Offering
Details : The Company intends to use the net proceeds from this offering to fund its clinical development programs, commercialization activities and for acquisitions and general corporate purposes.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
January 11, 2021
Lead Product(s) : Clarithromycin,Clofazimine,Rifabutin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : H.C. Wainwright & Co
Deal Size : $10.0 million
Deal Type : Public Offering

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Can Fite is exploring the possibility to collaborate with leading virology labs to explore the anti-viral effect of its drugs against the Coronavirus based on the known anti-viral effects.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 05, 2020
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Can-Fite Completes 50% Patient Enrollment in Phase III RA Study
Details : The Phase III ACRobat™ RA study is designed to establish Piclidenoson’s superiority compared to placebo and non-inferiority compared to methotrexate in patients with RA.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
February 03, 2020
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Clarithromycin
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Clarithromycin is a Antibiotic drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Crohn Disease.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
January 04, 2017
Lead Product(s) : Clarithromycin
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
CF101 Therapy Compared to Methotrexate Therapy for Active Rheumatoid Arthritis
Details : CF101 is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Arthritis, Rheumatoid.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 06, 2016
Lead Product(s) : Piclidenoson
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Azelastine HCl is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 25, 2014
Lead Product(s) : Azelastine Hydrochloride
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Fluticasone Propionate is a Steroid drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Rhinitis, Allergic, Seasonal.
Product Name : Undisclosed
Product Type : Steroid
Upfront Cash : Inapplicable
September 23, 2014
Lead Product(s) : Fluticasone Propionate
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
